As a result, cGAMP and STING agonists are being actively investigated as immunotherapeutics for the treatment of cancers and as mucosal adjuvants for the development of vaccines against infectious diseases (Gogoi et al., 2020; An et al., 2021; Petrovic et al., 2021; Wu et al., 2022). The gene discussed is STING1; the disease is cancer.